![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its d... Black Diamond Therapeutics Inc is a precision oncology medicine company. It is engaged in the discovery and development of small molecule, tumor-agnostic therapies. The company has one pipeline technology platform, namely Mutation-Allostery-Pharmacology, which is targeting mutations in cancer. Its drugs under pipeline are BDTX-189 and BDTX-1535. Show more
Results from Phase 1 dose escalation trial of BDTX-1535 in GBM patients demonstrated a favorable safety and tolerability profile, and encouraging anti-tumor activity and duration of treatment...
CAMBRIDGE, Mass., May 29, 2024 (GLOBE NEWSWIRE) -- Black Diamond Therapeutics, Inc. (Nasdaq: BDTX), a clinical-stage oncology company developing MasterKey therapies that target families of...
Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data...
Period † | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.34 | -6.8 | 5 | 5.0841 | 4.52 | 576490 | 4.74128243 | CS |
4 | -0.1 | -2.10084033613 | 4.76 | 6.41 | 4.41 | 597752 | 5.33653798 | CS |
12 | -0.44 | -8.62745098039 | 5.1 | 7.66 | 4.41 | 704515 | 5.54260013 | CS |
26 | 1.67 | 55.8528428094 | 2.99 | 7.66 | 2.53 | 638355 | 4.91444479 | CS |
52 | -1.19 | -20.3418803419 | 5.85 | 7.66 | 1.62 | 791417 | 4.4037427 | CS |
156 | -8.3 | -64.0432098765 | 12.96 | 12.96 | 1.18 | 675607 | 5.14825262 | CS |
260 | -28.34 | -85.8787878788 | 33 | 46.25 | 1.18 | 573663 | 9.2271226 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions